Osteoporosis – 1st part, etiopathogenesis, risk factors and diagnostics

Petra Matalová

Prakt. Lékáren. 2019; 15(2e): e11-e20  

Osteoporosis is considered to be a disease prevails highly not only in the most developed industrial countries. As a chronic disease of the skeleton it is characterised by the decrease of bone density with deterioration of bone microstructure. Lowered bone strength is a result of quantitative and qualitative changes in the bone mass and this contributes to higher risk of fractures. Creation of the highest level of bone mass is the most important preventative factor. This can be achieved by consistent and appropriate physical activity and sufficient nutrition high in calcium, vitamin D and proteins. The diagnosis of osteoporosis is achieved either by...

The role of pharmacotherapy in the treatment of myasthenia gravis

Jiří Piťha

Prakt. Lékáren. 2019; 15(2e): e21-e29  

Myasthenia gravis is an autoimmune disease with antibody production against certain proteins on the postsynaptic membrane of the neuromusculardisorder, particularly the acetylcholine receptor. As a result, there is a manifestation of muscle weakness and fatigue. The treatmentconsists in the administration of symptomatic drugs, but influencing the immunopathogenesis of the disease, however, lies in the long-termadministration of immunosuppressive agents or immunomodulators. This treatment may be nonspecific with the reduction of autoreactive B or T lymphocytes or specific by monoclonal antibodies that target cell surface features....

Hypnotic drugs in treating insomnia

Martin Pretl

Prakt. Lékáren. 2019; 15(2e): e30-e38  

Insomnia is defined as a persistent difficulty with sleep initiation, duration, or quality despite adequate circumstances for good-quality sleep, thus affecting the quality of life, daily functioning, and even causing somatic symptoms. The International Classification of Sleep Disorders divides insomnia into chronic (for a minimum period of three months, for at least three times a week) and acute. Chronic insomnia affects at least 5–10% of the population. Nonpharmacological treatment – psychotherapy is recommended as first-line treatment for insomnia. The best effect is achieved with cognitive behavioural therapy. Only if this treatment...

Amiodarone induced acute hepatotoxicity during intravenous application

Jana Ďuricová, Marcela Káňová, Ivana Kacířová

Prakt. Lékáren. 2019; 15(2e): e3-e10  

Amiodarone is considered a very effective agent in the treatment of supraventricular and ventricular arrhythmias. It has a good haemodynamic profile with a low arrhythmogenic risk. However, its use is associated with many cardiac and extracardiac adverse effects. Hepatotoxicity during long-term amiodarone administration is relatively frequent. Asymptomatic elevation of transaminases is reported with incidence about 25 %, with normalisation after dose reduction or amiodarone discontinuation. On the other hand, acute hepatotoxicity during intravenous amiodarone application is rare. This article presents a case of a patient admitted to the intensive care...

50 let Farmaceutické fakulty Univerzity Karlovy v Hradci Králové

Martin Doležal, Tomáš Šimůnek

Prakt. Lékáren. 2019; 15(2e): e39-e41  

Konference mladých lékárníků v Opavě

Marie Zajícová

Prakt. Lékáren. 2019; 15(2e): e42-e43  

E-verze 2/19

Prakt. Lékáren. 2019; 15(2e)